Saturday, December 21, 2024
12/21/2024
Cardiovascular diseases remain the leading cause of deaths globally, representing approximately 31% of deaths per year, 85% of which are due to myocardial infarction (MI) or stroke. This does not account for the millions of patients suffering daily with current therapies that are not efficacious in treating a major cause of cardiovascular disease: atherosclerosis. Current therapeutics for atherosclerosis fail to consider the role of dampening inflammation and improving lymphatic function, both of which have the potential to promote plaque regression. Lymphangiogenesis is the process where the lymphatic network is extended, but its role in atherogenesis is currently under-characterized and controversial. Inflammatory diseases are found to have lymphangiogenesis with associated malfunction, but controversy exists as to whether this is a cause of disease pathogenesis or a compensatory attempt at disease resolution. Recent data suggests a role for lymphatic vessels in reverse cholesterol transport (RCT), which relies on the junctional morphology between lymphatic endothelial cells (LECs) to regulate the egression of HDL and/or inflammatory cells. During inflammation, junctions between LECs transform from discontinuous buttons to impermeable zippers, which may impede RCT and prevent resolution of inflammation. Our lab has previously reported that Interleukin-19 (IL-19), an immuno-modulatory cytokine, uniquely attenuates atherosclerotic plaque progression while also being pro-angiogenic. This drives our central hypothesis that one mechanism whereby IL-19 prevents atherosclerotic disease progression is by driving functional lymphangiogenesis, especially through the maintenance of permeable lymphatic vessels to promote RCT. Our in vitro data indicates IL-19 can significantly induce primary LEC proliferation, migration, and tube formation, all lymphangiogenic assays. RNA sequencing also identified upregulation of Prox1, the master transcription factor of lymphangiogenesis, 6.2-fold. IL-19 also increases expression of several genes implicated in endothelial cell permeability, including Angpt2. Functional in vitro permeability assays showed that oxLDL decreases LEC permeability which IL-19 treatment prevents. This suggested that IL-19 can promote transport of lipid through lymphatic vessels and was confirmed with HDL transit. Junctional morphology was also validated via immunocytochemistry for VE-cadherin on hdLECs. Western blot confirmed phosphorylation of STAT3, a factor in canonical IL-19 signaling, and VE-cadherin, an indication of LEC permeability. Subsequent Prox1 siRNA knockdown mitigated both IL-19 stimulated lymphangiogenesis and Angpt2 upregulation. Preliminary in vivo data with VEcadCreERT2 Prox1 F/+ mice, which experience compromised lymphatic function, indicates that IL-19 improves lymphatic function through removal of Evans blue dye. These data suggest that IL-19 increases lymphatic vessel formation and function, with a potential mechanism of enhancing RCT to decrease plaque burden in atherosclerosis. This grant will continue to characterize IL-19’s mechanistic pathway in LECs and determine lymphatic functionality in vivo through HDL and foam cell trafficking by aortic microlymphangiography.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).